{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T11:07:52Z","timestamp":1771585672363,"version":"3.50.1"},"reference-count":90,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,2,20]]},"DOI":"10.7759\/cureus.103951","type":"journal-article","created":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T10:22:12Z","timestamp":1771582932000},"source":"Crossref","is-referenced-by-count":0,"title":["Digital Medicine and Artificial Intelligence in Chronic Myeloid Leukemia: Current Applications, Challenges, and Future Directions"],"prefix":"10.7759","author":[{"given":"Chingiz","family":"Asadov","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aytan","family":"Shirinova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zohra","family":"Alimirzoyeva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aypara","family":"Hasanova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1609324","article-title":"Long-term outcomes of imatinib treatment for chronic myeloid leukemia","volume":"376","author":"Hochhaus A","year":"2017","unstructured":"Hochhaus A, Larson RA, Guilhot F, et al.. Long-term outcomes of imatinib treatment for chronic myeloid leukemia. N Engl J Med. 2017, 376:917-27. 10.1056\/NEJMoa1609324","journal-title":"N Engl J Med"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.27443","article-title":"Chronic myeloid leukemia: 2025 update on diagnosis, therapy, and monitoring","volume":"99","author":"Jabbour E","year":"2024","unstructured":"Jabbour E, Kantarjian H. Chronic myeloid leukemia: 2025 update on diagnosis, therapy, and monitoring. Am J Hematol. 2024, 99:2191-212. 10.1002\/ajh.27443","journal-title":"Am J Hematol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-024-12764-y","article-title":"Application of artificial intelligence in chronic myeloid leukemia (CML) disease prediction and management: a scoping review","volume":"24","author":"Ram M","year":"2024","unstructured":"Ram M, Afrash MR, Moulaei K, et al.. Application of artificial intelligence in chronic myeloid leukemia (CML) disease prediction and management: a scoping review. BMC Cancer. 2024, 24:1026. 10.1186\/s12885-024-12764-y","journal-title":"BMC Cancer"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2018.12.013","article-title":"The case for real-world evidence in the future of clinical research on chronic myeloid leukemia","volume":"41","author":"Webster J","year":"2019","unstructured":"Webster J, Smith BD. The case for real-world evidence in the future of clinical research on chronic myeloid leukemia. Clin Ther. 2019, 41:336-49. 10.1016\/j.clinthera.2018.12.013","journal-title":"Clin Ther"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.glmedi.2024.100118","article-title":"An autopsy presentation of spontaneous splenic rupture in chronic myeloid leukemia: a rare case report","author":"Kanani J","year":"2024","unstructured":"Kanani J, Sheikh MI. An autopsy presentation of spontaneous splenic rupture in chronic myeloid leukemia: a rare case report. J Med Surg Public Health. 2024, 10.1016\/j.glmedi.2024.100118","journal-title":"J Med Surg Public Health"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1186\/s12913-023-09153-9","article-title":"Effectiveness of digital care platform CMyLife for patients with chronic myeloid leukemia: results of a patient-preference trial","volume":"23","author":"Verweij L","year":"2023","unstructured":"Verweij L, Ector GI, Smit Y, van Vlijmen B, van der Reijden BA, Hermens RP, Blijlevens NM. Effectiveness of digital care platform CMyLife for patients with chronic myeloid leukemia: results of a patient-preference trial. BMC Health Serv Res. 2023, 23:228. 10.1186\/s12913-023-09153-9","journal-title":"BMC Health Serv Res"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-09727-z","article-title":"Enhancing remote patient monitoring with AI-driven IoMT and cloud computing technologies","volume":"15","author":"Damera VK","year":"2025","unstructured":"Damera VK, Cheripelli R, Putta N, Sirisha G, Kalavala D. Enhancing remote patient monitoring with AI-driven IoMT and cloud computing technologies. Sci Rep. 2025, 15:24088. 10.1038\/s41598-025-09727-z","journal-title":"Sci Rep"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2025.1673056","article-title":"In-depth analysis for TKI-driven real-world management of 201 CML patients using TFR","volume":"16","author":"Micu ML","year":"2025","unstructured":"Micu ML, Cira SF, Zdrenghea M, et al.. In-depth analysis for TKI-driven real-world management of 201 CML patients using TFR. Front Pharmacol. 2025, 16:1673056. 10.3389\/fphar.2025.1673056","journal-title":"Front Pharmacol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.3390\/info16060487","article-title":"Advances in application of federated machine learning for oncology and cancer diagnosis","volume":"16","author":"Nasajpour M","year":"2025","unstructured":"Nasajpour M, Pouriyeh S, Parizi RM, et al.. Advances in application of federated machine learning for oncology and cancer diagnosis. Information. 2025, 16:487. 10.3390\/info16060487","journal-title":"Information"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1002\/hem3.70048","article-title":"Models for the marrow: a comprehensive review of AI-based cell classification methods and malignancy detection in bone marrow aspirate smears","volume":"8","author":"Ghete T","year":"2024","unstructured":"Ghete T, Kock F, Pontones M, Pfrang D, Westphal M, H\u00f6fener H, Metzler M. Models for the marrow: a comprehensive review of AI-based cell classification methods and malignancy detection in bone marrow aspirate smears. Hemasphere. 2024, 8:e70048. 10.1002\/hem3.70048","journal-title":"Hemasphere"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-40424-x","article-title":"High-accuracy morphological identification of bone marrow cells using deep learning-based Morphogo system","volume":"13","author":"Lv Z","year":"2023","unstructured":"Lv Z, Cao X, Jin X, Xu S, Deng H. High-accuracy morphological identification of bone marrow cells using deep learning-based Morphogo system. Sci Rep. 2023, 13:13364. 10.1038\/s41598-023-40424-x","journal-title":"Sci Rep"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1111\/ijlh.14533","article-title":"Digital pathology in hematopathology: from vision to deployment","author":"Shean RC","year":"2025","unstructured":"Shean RC, Rets AV. Digital pathology in hematopathology: from vision to deployment. Int J Lab Hematol. 2025, 10.1111\/ijlh.14533","journal-title":"Int J Lab Hematol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajpath.2022.03.016","article-title":"The diagnosis of chronic myeloid leukemia with deep adversarial learning","volume":"192","author":"Zhang Z","year":"2022","unstructured":"Zhang Z, Huang X, Yan Q, et al.. The diagnosis of chronic myeloid leukemia with deep adversarial learning. Am J Pathol. 2022, 192:1083-91. 10.1016\/j.ajpath.2022.03.016","journal-title":"Am J Pathol"},{"key":"ref14","article-title":"Segmentation of white blood cells from microscopic images using a novel combination of K-means clustering and modified watershed algorithm","volume":"7","author":"Ghane N","year":"2017","unstructured":"Ghane N, Vard A, Talebi A, Nematollahy P. Segmentation of white blood cells from microscopic images using a novel combination of K-means clustering and modified watershed algorithm. J Med Signals Sens. 2017, 7:92-101.","journal-title":"J Med Signals Sens"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-26947-5","article-title":"Efficient blood cell classification from microscopic smear images using U-Net segmentation and a lightweight CNN","volume":"15","author":"Mondal SK","year":"2025","unstructured":"Mondal SK, Talukder MS, Aljaidi M, Sulaiman RB, Tushar MM, Alsuwaylimi AA. Efficient blood cell classification from microscopic smear images using U-Net segmentation and a lightweight CNN. Sci Rep. 2025, 15:45693. 10.1038\/s41598-025-26947-5","journal-title":"Sci Rep"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1002\/jbio.202500121","article-title":"Unstained blood smear analysis: a review of rule-based, machine learning, and deep learning techniques","volume":"18","author":"Baydargil HB","year":"2025","unstructured":"Baydargil HB, Bocklitz T. Unstained blood smear analysis: a review of rule-based, machine learning, and deep learning techniques. J Biophotonics. 2025, 18:e202500121. 10.1002\/jbio.202500121","journal-title":"J Biophotonics"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1038\/nmeth.2365","article-title":"Critical assessment of automated flow cytometry data analysis techniques","volume":"10","author":"Aghaeepour N","year":"2013","unstructured":"Aghaeepour N, Finak G, Hoos H, Mosmann TR, Brinkman R, Gottardo R, Scheuermann RH. Critical assessment of automated flow cytometry data analysis techniques. Nat Methods. 2013, 10:228-38. 10.1038\/nmeth.2365","journal-title":"Nat Methods"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.17992","article-title":"Flow cytometric minimal residual disease assessment in B-cell precursor acute lymphoblastic leukaemia patients treated with CD19-targeted therapies - a EuroFlow study","volume":"197","author":"Verbeek MW","year":"2022","unstructured":"Verbeek MW, Buracchi C, Laqua A, et al.. Flow cytometric minimal residual disease assessment in B-cell precursor acute lymphoblastic leukaemia patients treated with CD19-targeted therapies - a EuroFlow study. Br J Haematol. 2022, 197:76-81. 10.1111\/bjh.17992","journal-title":"Br J Haematol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14071653","article-title":"Acute hematological toxicity during cranio-spinal proton therapy in pediatric brain embryonal tumors","volume":"14","author":"Vennarini S","year":"2022","unstructured":"Vennarini S, Del Baldo G, Lorentini S, et al.. Acute hematological toxicity during cranio-spinal proton therapy in pediatric brain embryonal tumors. Cancers (Basel). 2022, 14:1653. 10.3390\/cancers14071653","journal-title":"Cancers (Basel)"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.3390\/genes16060685","article-title":"The emergence of artificial intelligence-guided karyotyping: a review and reflection","volume":"16","author":"Rosenblum LS","year":"2025","unstructured":"Rosenblum LS, Holmes J, Taghiyev AF. The emergence of artificial intelligence-guided karyotyping: a review and reflection. Genes (Basel). 2025, 16:685. 10.3390\/genes16060685","journal-title":"Genes (Basel)"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/j.compbiomed.2024.108601","article-title":"KaryoXpert: an accurate chromosome segmentation and classification framework for karyotyping analysis without training with manually labeled metaphase-image mask annotations","volume":"177","author":"Chen S","year":"2024","unstructured":"Chen S, Zhang K, Hu J, et al.. KaryoXpert: an accurate chromosome segmentation and classification framework for karyotyping analysis without training with manually labeled metaphase-image mask annotations. Comput Biol Med. 2024, 177:108601. 10.1016\/j.compbiomed.2024.108601","journal-title":"Comput Biol Med"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26062535","article-title":"Utilization of machine learning in the prediction, diagnosis, prognosis, and management of chronic myeloid leukemia","volume":"26","author":"Stagno F","year":"2025","unstructured":"Stagno F, Russo S, Murdaca G, et al.. Utilization of machine learning in the prediction, diagnosis, prognosis, and management of chronic myeloid leukemia. Int J Mol Sci. 2025, 26:2535. 10.3390\/ijms26062535","journal-title":"Int J Mol Sci"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1158\/2643-3230.BCD-20-0162","article-title":"Machine learning of bone marrow histopathology identifies genetic and clinical determinants in patients with MDS","volume":"2","author":"Br\u00fcck OE","year":"2021","unstructured":"Br\u00fcck OE, Lallukka-Br\u00fcck SE, Hohtari HR, et al.. Machine learning of bone marrow histopathology identifies genetic and clinical determinants in patients with MDS. Blood Cancer Discov. 2021, 2:238-49. 10.1158\/2643-3230.BCD-20-0162","journal-title":"Blood Cancer Discov"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1159\/000529701","article-title":"Artificial intelligence in bone marrow histological diagnostics: potential applications and challenges","volume":"91","author":"van Eekelen L","year":"2024","unstructured":"van Eekelen L, Litjens G, Hebeda KM. Artificial intelligence in bone marrow histological diagnostics: potential applications and challenges. Pathobiology. 2024, 91:8-17. 10.1159\/000529701","journal-title":"Pathobiology"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000023154","article-title":"AML, ALL, and CML classification and diagnosis based on bone marrow cell morphology combined with convolutional neural network: a STARD compliant diagnosis research","volume":"99","author":"Huang F","year":"2020","unstructured":"Huang F, Guang P, Li F, Liu X, Zhang W, Huang W. AML, ALL, and CML classification and diagnosis based on bone marrow cell morphology combined with convolutional neural network: a STARD compliant diagnosis research. Medicine (Baltimore). 2020, 99:e23154. 10.1097\/MD.0000000000023154","journal-title":"Medicine (Baltimore)"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2021-152447","article-title":"Automated peripheral blood cell differentiation using artificial intelligence - a study with more than 10,000 routine samples in a specialized leukemia laboratory","volume":"138","author":"Haferlach T","year":"2021","unstructured":"Haferlach T, Pohlkamp C, Heo I, et al.. Automated peripheral blood cell differentiation using artificial intelligence - a study with more than 10,000 routine samples in a specialized leukemia laboratory. Blood. 2021, 138:103. 10.1182\/blood-2021-152447","journal-title":"Blood"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1016\/j.apsb.2025.05.036","article-title":"Application of artificial intelligence in laboratory hematology: advances, challenges, and prospects","volume":"15","author":"Liao H","year":"2025","unstructured":"Liao H, Zhang F, Chen F, et al.. Application of artificial intelligence in laboratory hematology: advances, challenges, and prospects. Acta Pharm Sin B. 2025, 15:5702-33. 10.1016\/j.apsb.2025.05.036","journal-title":"Acta Pharm Sin B"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-06664-9","article-title":"Artificial intelligence-driven label-free detection of chronic myeloid leukemia cells using ghost cytometry","volume":"15","author":"Suzuki K","year":"2025","unstructured":"Suzuki K, Watanabe N, Tsukune Y, et al.. Artificial intelligence-driven label-free detection of chronic myeloid leukemia cells using ghost cytometry. Sci Rep. 2025, 15:21046. 10.1038\/s41598-025-06664-9","journal-title":"Sci Rep"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2021.06.025","article-title":"Accurate machine-learning-based classification of leukemia from blood smear images","volume":"21","author":"Dese K","year":"2021","unstructured":"Dese K, Raj H, Ayana G, Yemane T, Adissu W, Krishnamoorthy J, Kwa T. Accurate machine-learning-based classification of leukemia from blood smear images. Clin Lymphoma Myeloma Leuk. 2021, 21:e903-14. 10.1016\/j.clml.2021.06.025","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020010568","article-title":"Highly accurate differentiation of bone marrow cell morphologies using deep neural networks on a large image data set","volume":"138","author":"Matek C","year":"2021","unstructured":"Matek C, Krappe S, M\u00fcnzenmayer C, Haferlach T, Marr C. Highly accurate differentiation of bone marrow cell morphologies using deep neural networks on a large image data set. Blood. 2021, 138:1917-27. 10.1182\/blood.2020010568","journal-title":"Blood"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-58580-z","article-title":"Deep learning assists in acute leukemia detection and cell classification via flow cytometry using the acute leukemia orientation tube","volume":"14","author":"Cheng FM","year":"2024","unstructured":"Cheng FM, Lo SC, Lin CC, Lo WJ, Chien SY, Sun TH, Hsu KC. Deep learning assists in acute leukemia detection and cell classification via flow cytometry using the acute leukemia orientation tube. Sci Rep. 2024, 14:8350. 10.1038\/s41598-024-58580-z","journal-title":"Sci Rep"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16050848","article-title":"Artificial intelligence-based management of adult chronic myeloid leukemia: where are we and where are we going?","volume":"16","author":"Bernardi S","year":"2024","unstructured":"Bernardi S, Vallati M, Gatta R. Artificial intelligence-based management of adult chronic myeloid leukemia: where are we and where are we going?. Cancers (Basel). 2024, 16:848. 10.3390\/cancers16050848","journal-title":"Cancers (Basel)"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1186\/s12911-022-01980-w","article-title":"Comparing machine learning algorithms to predict 5-year survival in patients with chronic myeloid leukemia","volume":"22","author":"Shanbehzadeh M","year":"2022","unstructured":"Shanbehzadeh M, Afrash MR, Mirani N, Kazemi-Arpanahi H. Comparing machine learning algorithms to predict 5-year survival in patients with chronic myeloid leukemia. BMC Med Inform Decis Mak. 2022, 22:236. 10.1186\/s12911-022-01980-w","journal-title":"BMC Med Inform Decis Mak"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26047","article-title":"The LEukemia Artificial Intelligence Program (LEAP) in chronic myeloid leukemia in chronic phase: a model to improve patient outcomes","volume":"96","author":"Sasaki K","year":"2021","unstructured":"Sasaki K, Jabbour EJ, Ravandi F, et al.. The LEukemia Artificial Intelligence Program (LEAP) in chronic myeloid leukemia in chronic phase: a model to improve patient outcomes. Am J Hematol. 2021, 96:241-50. 10.1002\/ajh.26047","journal-title":"Am J Hematol"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-02-832253","article-title":"Integrative genomic analysis reveals cancer-associated mutations at diagnosis of CML in patients with high-risk disease","volume":"132","author":"Branford S","year":"2018","unstructured":"Branford S, Wang P, Yeung DT, et al.. Integrative genomic analysis reveals cancer-associated mutations at diagnosis of CML in patients with high-risk disease. Blood. 2018, 132:948-61. 10.1182\/blood-2018-02-832253","journal-title":"Blood"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2021.279317","article-title":"Integrating genetic and epigenetic factors in chronic myeloid leukemia risk assessment: toward gene expression-based biomarkers","volume":"107","author":"Krishnan V","year":"2022","unstructured":"Krishnan V, Kim DD, Hughes TP, Branford S, Ong ST. Integrating genetic and epigenetic factors in chronic myeloid leukemia risk assessment: toward gene expression-based biomarkers. Haematologica. 2022, 107:358-70. 10.3324\/haematol.2021.279317","journal-title":"Haematologica"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2022.281878","article-title":"Molecular response in newly diagnosed chronic-phase chronic myeloid leukemia: prediction modeling and pathway analysis","volume":"108","author":"Radich JP","year":"2023","unstructured":"Radich JP, Wall M, Branford S, et al.. Molecular response in newly diagnosed chronic-phase chronic myeloid leukemia: prediction modeling and pathway analysis. Haematologica. 2023, 108:1567-78. 10.3324\/haematol.2022.281878","journal-title":"Haematologica"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-11-4687","article-title":"OCT-1-mediated influx is a key determinant of the intracellular uptake of imatinib but not nilotinib (AMN107): reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinib","volume":"108","author":"White DL","year":"2006","unstructured":"White DL, Saunders VA, Dang P, et al.. OCT-1-mediated influx is a key determinant of the intracellular uptake of imatinib but not nilotinib (AMN107): reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinib. Blood. 2006, 108:697-704. 10.1182\/blood-2005-11-4687","journal-title":"Blood"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-015-2905-6","article-title":"A study to explore the correlation of ABCB1, ABCG2, OCT1 genetic polymorphisms and trough level concentration with imatinib mesylate-induced thrombocytopenia in chronic myeloid leukemia patients","volume":"76","author":"Francis J","year":"2015","unstructured":"Francis J, Dubashi B, Sundaram R, Pradhan SC, Chandrasekaran A. A study to explore the correlation of ABCB1, ABCG2, OCT1 genetic polymorphisms and trough level concentration with imatinib mesylate-induced thrombocytopenia in chronic myeloid leukemia patients. Cancer Chemother Pharmacol. 2015, 76:1185-9. 10.1007\/s00280-015-2905-6","journal-title":"Cancer Chemother Pharmacol"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-10-745992","article-title":"CML patients with deep molecular responses to TKI have restored immune effectors and decreased PD-1 and immune suppressors","volume":"129","author":"Hughes A","year":"2017","unstructured":"Hughes A, Clarson J, Tang C, Vidovic L, White DL, Hughes TP, Yong AS. CML patients with deep molecular responses to TKI have restored immune effectors and decreased PD-1 and immune suppressors. Blood. 2017, 129:1166-76. 10.1182\/blood-2016-10-745992","journal-title":"Blood"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-018-0175-0","article-title":"Immune cell contexture in the bone marrow tumor microenvironment impacts therapy response in CML","volume":"32","author":"Br\u00fcck O","year":"2018","unstructured":"Br\u00fcck O, Blom S, Dufva O, et al.. Immune cell contexture in the bone marrow tumor microenvironment impacts therapy response in CML. Leukemia. 2018, 32:1643-56. 10.1038\/s41375-018-0175-0","journal-title":"Leukemia"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics13071330","article-title":"Applications of machine learning in chronic myeloid leukemia","volume":"13","author":"Elhadary M","year":"2023","unstructured":"Elhadary M, Elsabagh AA, Ferih K, et al.. Applications of machine learning in chronic myeloid leukemia. Diagnostics (Basel). 2023, 13:1330. 10.3390\/diagnostics13071330","journal-title":"Diagnostics (Basel)"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2024.107502","article-title":"Prediction of deep molecular response in chronic myeloid leukemia using supervised machine learning models","volume":"141","author":"Zad Z","year":"2024","unstructured":"Zad Z, Bonecker S, Wang T, et al.. Prediction of deep molecular response in chronic myeloid leukemia using supervised machine learning models. Leuk Res. 2024, 141:107502. 10.1016\/j.leukres.2024.107502","journal-title":"Leuk Res"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.31411","article-title":"Discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia: recommendations for clinical practice from the French Chronic Myeloid Leukemia Study Group","volume":"124","author":"Rea D","year":"2018","unstructured":"Rea D, Ame S, Berger M, et al.. Discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia: recommendations for clinical practice from the French Chronic Myeloid Leukemia Study Group. Cancer. 2018, 124:2956-63. 10.1002\/cncr.31411","journal-title":"Cancer"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(10)70233-3","article-title":"Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial","volume":"11","author":"Mahon FX","year":"2010","unstructured":"Mahon FX, R\u00e9a D, Guilhot J, et al.. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol. 2010, 11:1029-35. 10.1016\/S1470-2045(10)70233-3","journal-title":"Lancet Oncol"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2025-76","article-title":"A machine learning approach identifies a transcriptomic signature predicting treatment-free remission in chronic myeloid leukemia","volume":"146","author":"Alcazer V","year":"2025","unstructured":"Alcazer V, Dulucq S, Mosnier I, et al.. A machine learning approach identifies a transcriptomic signature predicting treatment-free remission in chronic myeloid leukemia. Blood. 2025, 146:76. 10.1182\/blood-2025-76","journal-title":"Blood"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1038\/s41540-025-00598-8","article-title":"Predicting treatment-free remission in chronic myeloid leukemia patients using an integrated model of tumor-immune dynamics","volume":"11","author":"Fassoni AC","year":"2025","unstructured":"Fassoni AC, Yong AS, Clark RE, Roeder I, Glauche I. Predicting treatment-free remission in chronic myeloid leukemia patients using an integrated model of tumor-immune dynamics. NPJ Syst Biol Appl. 2025, 11:115. 10.1038\/s41540-025-00598-8","journal-title":"NPJ Syst Biol Appl"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020005514","article-title":"Early BCR-ABL1 kinetics are predictive of subsequent achievement of treatment-free remission in chronic myeloid leukemia","volume":"137","author":"Shanmuganathan N","year":"2021","unstructured":"Shanmuganathan N, Pagani IS, Ross DM, et al.. Early BCR-ABL1 kinetics are predictive of subsequent achievement of treatment-free remission in chronic myeloid leukemia. Blood. 2021, 137:1196-207. 10.1182\/blood.2020005514","journal-title":"Blood"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10010042","article-title":"Identification of immunological parameters as predictive biomarkers of relapse in patients with chronic myeloid leukemia on treatment-free remission","volume":"10","author":"Vig\u00f3n L","year":"2020","unstructured":"Vig\u00f3n L, Luna A, Gal\u00e1n M, et al.. Identification of immunological parameters as predictive biomarkers of relapse in patients with chronic myeloid leukemia on treatment-free remission. J Clin Med. 2020, 10:42. 10.3390\/jcm10010042","journal-title":"J Clin Med"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0168947","article-title":"Modelling predictors of molecular response to frontline imatinib for patients with chronic myeloid leukaemia","volume":"12","author":"Banjar H","year":"2017","unstructured":"Banjar H, Ranasinghe D, Brown F, et al.. Modelling predictors of molecular response to frontline imatinib for patients with chronic myeloid leukaemia. PLoS One. 2017, 12:e0168947. 10.1371\/journal.pone.0168947","journal-title":"PLoS One"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-202876","article-title":"Predictive models for discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia","volume":"144","author":"Cheng F","year":"2024","unstructured":"Cheng F, Wang Y, Du X, et al.. Predictive models for discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia. Blood. 2024, 144:4540. 10.1182\/blood-2024-202876","journal-title":"Blood"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30192-X","article-title":"Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial","volume":"19","author":"Saussele S","year":"2018","unstructured":"Saussele S, Richter J, Guilhot J, et al.. Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial. Lancet Oncol. 2018, 19:747-57. 10.1016\/S1470-2045(18)30192-X","journal-title":"Lancet Oncol"},{"key":"ref53","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2025.0220","article-title":"Chronic myeloid leukemia: a review","volume":"333","author":"Jabbour E","year":"2025","unstructured":"Jabbour E, Kantarjian H. Chronic myeloid leukemia: a review. JAMA. 2025, 333:1618-29. 10.1001\/jama.2025.0220","journal-title":"JAMA"},{"key":"ref54","doi-asserted-by":"publisher","DOI":"10.1126\/science.aan0096","article-title":"Ghost cytometry","volume":"360","author":"Ota S","year":"2018","unstructured":"Ota S, Horisaki R, Kawamura Y, et al.. Ghost cytometry. Science. 2018, 360:1246-51. 10.1126\/science.aan0096","journal-title":"Science"},{"key":"ref55","doi-asserted-by":"publisher","DOI":"10.1093\/ajcp\/aqab086","article-title":"A machine learning model to successfully predict future diagnosis of chronic myelogenous leukemia with retrospective electronic health records data","volume":"156","author":"Hauser RG","year":"2021","unstructured":"Hauser RG, Esserman D, Beste LA, et al.. A machine learning model to successfully predict future diagnosis of chronic myelogenous leukemia with retrospective electronic health records data. Am J Clin Pathol. 2021, 156:1142-8. 10.1093\/ajcp\/aqab086","journal-title":"Am J Clin Pathol"},{"key":"ref56","doi-asserted-by":"publisher","DOI":"10.1039\/d5md00494b","article-title":"Leveraging artificial intelligence and machine learning in kinase inhibitor development: advances, challenges, and future prospects","author":"Elgawish MS","year":"2025","unstructured":"Elgawish MS, Almatary AM, Zaitone SA, Salem MS. Leveraging artificial intelligence and machine learning in kinase inhibitor development: advances, challenges, and future prospects. RSC Med Chem. 2025, 10.1039\/d5md00494b","journal-title":"RSC Med Chem"},{"key":"ref57","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines11041041","article-title":"Artificial intelligence assisted pharmacophore design for Philadelphia chromosome-positive leukemia with gamma-tocotrienol: a toxicity comparison approach with asciminib","volume":"11","author":"Naveed M","year":"2023","unstructured":"Naveed M, Ain NU, Aziz T, et al.. Artificial intelligence assisted pharmacophore design for Philadelphia chromosome-positive leukemia with gamma-tocotrienol: a toxicity comparison approach with asciminib. Biomedicines. 2023, 11:1041. 10.3390\/biomedicines11041041","journal-title":"Biomedicines"},{"key":"ref58","doi-asserted-by":"publisher","DOI":"10.3389\/fchem.2019.00873","article-title":"In silico methods for design of kinase inhibitors as anticancer drugs","volume":"7","author":"Gagic Z","year":"2019","unstructured":"Gagic Z, Ruzic D, Djokovic N, Djikic T, Nikolic K. In silico methods for design of kinase inhibitors as anticancer drugs. Front Chem. 2019, 7:873. 10.3389\/fchem.2019.00873","journal-title":"Front Chem"},{"key":"ref59","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2023.103551","article-title":"AlphaFold, allosteric, and orthosteric drug discovery: ways forward","volume":"28","author":"Nussinov R","year":"2023","unstructured":"Nussinov R, Zhang M, Liu Y, Jang H. AlphaFold, allosteric, and orthosteric drug discovery: ways forward. Drug Discov Today. 2023, 28:103551. 10.1016\/j.drudis.2023.103551","journal-title":"Drug Discov Today"},{"key":"ref60","doi-asserted-by":"publisher","DOI":"10.3390\/biom15091214","article-title":"Exploring the allosteric pathways of asciminib in the dual inhibition of BCR-ABL1","volume":"15","author":"Ming J","year":"2025","unstructured":"Ming J, Gao H, Zhan J. Exploring the allosteric pathways of asciminib in the dual inhibition of BCR-ABL1. Biomolecules. 2025, 15:1214. 10.3390\/biom15091214","journal-title":"Biomolecules"},{"key":"ref61","doi-asserted-by":"publisher","DOI":"10.3390\/biom12020212","article-title":"Computational identification of BCR-ABL oncogenic signaling as a candidate target of withaferin A and withanone","volume":"12","author":"Malik V","year":"2022","unstructured":"Malik V, Radhakrishnan N, Kaul SC, Wadhwa R, Sundar D. Computational identification of BCR-ABL oncogenic signaling as a candidate target of withaferin A and withanone. Biomolecules. 2022, 12:212. 10.3390\/biom12020212","journal-title":"Biomolecules"},{"key":"ref62","doi-asserted-by":"publisher","DOI":"10.1038\/s41746-020-0221-y","article-title":"An overview of clinical decision support systems: benefits, risks, and strategies for success","volume":"3","author":"Sutton RT","year":"2020","unstructured":"Sutton RT, Pincock D, Baumgart DC, Sadowski DC, Fedorak RN, Kroeker KI. An overview of clinical decision support systems: benefits, risks, and strategies for success. NPJ Digit Med. 2020, 3:17. 10.1038\/s41746-020-0221-y","journal-title":"NPJ Digit Med"},{"key":"ref63","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.57728","article-title":"AI-driven clinical decision support systems: an ongoing pursuit of potential","volume":"16","author":"Elhaddad M","year":"2024","unstructured":"Elhaddad M, Hamam S. AI-driven clinical decision support systems: an ongoing pursuit of potential. Cureus. 2024, 16:e57728. 10.7759\/cureus.57728","journal-title":"Cureus"},{"key":"ref64","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-022-01607-z","article-title":"Standardization of molecular monitoring of CML: results and recommendations from the European treatment and outcome study","volume":"36","author":"White HE","year":"2022","unstructured":"White HE, Salmon M, Albano F, et al.. Standardization of molecular monitoring of CML: results and recommendations from the European treatment and outcome study. Leukemia. 2022, 36:1834-42. 10.1038\/s41375-022-01607-z","journal-title":"Leukemia"},{"key":"ref65","doi-asserted-by":"publisher","DOI":"10.3390\/healthcare13172154","article-title":"Explainable AI in clinical decision support systems: a meta-analysis of methods, applications, and usability challenges","volume":"13","author":"Abbas Q","year":"2025","unstructured":"Abbas Q, Jeong W, Lee SW. Explainable AI in clinical decision support systems: a meta-analysis of methods, applications, and usability challenges. Healthcare (Basel). 2025, 13:2154. 10.3390\/healthcare13172154","journal-title":"Healthcare (Basel)"},{"key":"ref66","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbi.2020.103655","article-title":"The role of explainability in creating trustworthy artificial intelligence for health care: a comprehensive survey of the terminology, design choices, and evaluation strategies","volume":"113","author":"Markus AF","year":"2021","unstructured":"Markus AF, Kors JA, Rijnbeek PR. The role of explainability in creating trustworthy artificial intelligence for health care: a comprehensive survey of the terminology, design choices, and evaluation strategies. J Biomed Inform. 2021, 113:103655. 10.1016\/j.jbi.2020.103655","journal-title":"J Biomed Inform"},{"key":"ref67","doi-asserted-by":"publisher","DOI":"10.2196\/73374","article-title":"Improving explainability and integrability of medical AI to promote health care professional acceptance and use: mixed systematic review","volume":"27","author":"Liu Y","year":"2025","unstructured":"Liu Y, Liu C, Zheng J, Xu C, Wang D. Improving explainability and integrability of medical AI to promote health care professional acceptance and use: mixed systematic review. J Med Internet Res. 2025, 27:e73374. 10.2196\/73374","journal-title":"J Med Internet Res"},{"key":"ref68","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pdig.0000866","article-title":"The illusion of safety: a report to the FDA on AI healthcare product approvals","volume":"4","author":"Abulibdeh R","year":"2025","unstructured":"Abulibdeh R, Celi LA, Sejdi\u0107 E. The illusion of safety: a report to the FDA on AI healthcare product approvals. PLOS Digit Health. 2025, 4:e0000866. 10.1371\/journal.pdig.0000866","journal-title":"PLOS Digit Health"},{"key":"ref69","doi-asserted-by":"publisher","DOI":"10.1142\/9789819807024_0012","article-title":"Implications of an evolving regulatory landscape on the development of AI and ML in medicine","volume":"30","author":"Rincon N","year":"2025","unstructured":"Rincon N, Gerke S, Wagner JK. Implications of an evolving regulatory landscape on the development of AI and ML in medicine. Pac Symp Biocomput. 2025, 30:154-66. 10.1142\/9789819807024_0012","journal-title":"Pac Symp Biocomput"},{"key":"ref70","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2021.2626","article-title":"External validation of a widely implemented proprietary sepsis prediction model in hospitalized patients","volume":"181","author":"Wong A","year":"2021","unstructured":"Wong A, Otles E, Donnelly JP, et al.. External validation of a widely implemented proprietary sepsis prediction model in hospitalized patients. JAMA Intern Med. 2021, 181:1065-70. 10.1001\/jamainternmed.2021.2626","journal-title":"JAMA Intern Med"},{"key":"ref71","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2021.3333","article-title":"The Epic Sepsis Model falls short\u2014the importance of external validation","volume":"181","author":"Habib AR","year":"2021","unstructured":"Habib AR, Lin AL, Grant RW. The Epic Sepsis Model falls short\u2014the importance of external validation. JAMA Intern Med. 2021, 181:1040-1. 10.1001\/jamainternmed.2021.3333","journal-title":"JAMA Intern Med"},{"key":"ref72","doi-asserted-by":"publisher","DOI":"10.1001\/jamahealthforum.2025.3351","article-title":"Benefit-risk reporting for FDA-cleared artificial intelligence-enabled medical devices","volume":"6","author":"Lin JC","year":"2025","unstructured":"Lin JC, Jain B, Iyer JM, et al.. Benefit-risk reporting for FDA-cleared artificial intelligence-enabled medical devices. JAMA Health Forum. 2025, 6:e253351. 10.1001\/jamahealthforum.2025.3351","journal-title":"JAMA Health Forum"},{"key":"ref73","doi-asserted-by":"publisher","DOI":"10.1259\/bjr.20220878","article-title":"Data drift in medical machine learning: implications and potential remedies","volume":"96","author":"Sahiner B","year":"2023","unstructured":"Sahiner B, Chen W, Samala RK, Petrick N. Data drift in medical machine learning: implications and potential remedies. Br J Radiol. 2023, 96:20220878. 10.1259\/bjr.20220878","journal-title":"Br J Radiol"},{"key":"ref74","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0317276","article-title":"Patients' attitudes toward artificial intelligence (AI) in cancer care: a scoping review protocol","volume":"20","author":"Hilbers D","year":"2025","unstructured":"Hilbers D, Nekain N, Bates AT, Nunez JJ. Patients' attitudes toward artificial intelligence (AI) in cancer care: a scoping review protocol. PLoS One. 2025, 20:e0317276. 10.1371\/journal.pone.0317276","journal-title":"PLoS One"},{"key":"ref75","doi-asserted-by":"publisher","DOI":"10.1177\/10732748251343245","article-title":"Perceptions, attitudes, and concerns on artificial intelligence applications in patients with cancer","volume":"32","author":"Erul E","year":"2025","unstructured":"Erul E, Aktekin Y, Dan\u0131\u015fman FB, G\u00fcm\u00fc\u015fta\u015f \u015eA, Aktekin BS, Yeked\u00fcz E, \u00dcr\u00fcn Y. Perceptions, attitudes, and concerns on artificial intelligence applications in patients with cancer. Cancer Control. 2025, 32:10732748251343245. 10.1177\/10732748251343245","journal-title":"Cancer Control"},{"key":"ref76","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2019.5014","article-title":"Patient perspectives on the use of artificial intelligence for skin cancer screening: a qualitative study","volume":"156","author":"Nelson CA","year":"2020","unstructured":"Nelson CA, P\u00e9rez-Chada LM, Creadore A, et al.. Patient perspectives on the use of artificial intelligence for skin cancer screening: a qualitative study. JAMA Dermatol. 2020, 156:501-12. 10.1001\/jamadermatol.2019.5014","journal-title":"JAMA Dermatol"},{"key":"ref77","doi-asserted-by":"publisher","DOI":"10.1056\/AIoa2300032","article-title":"Evaluation of sepsis prediction models before onset of treatment","volume":"1","author":"Kamran F","year":"2024","unstructured":"Kamran F, Tjandra D, Heiler A, et al.. Evaluation of sepsis prediction models before onset of treatment. NEJM AI. 2024, 1:10.1056\/AIoa2300032","journal-title":"NEJM AI"},{"key":"ref78","doi-asserted-by":"publisher","DOI":"10.1038\/s41746-024-01094-9","article-title":"An operational guide to translational clinical machine learning in academic medical centers","volume":"7","author":"Poddar M","year":"2024","unstructured":"Poddar M, Marwaha JS, Yuan W, Romero-Brufau S, Brat GA. An operational guide to translational clinical machine learning in academic medical centers. NPJ Digit Med. 2024, 7:129. 10.1038\/s41746-024-01094-9","journal-title":"NPJ Digit Med"},{"key":"ref79","doi-asserted-by":"publisher","DOI":"10.1016\/j.mcpdig.2024.06.009","article-title":"Machine learning operations in health care: a scoping review","volume":"2","author":"Rajagopal A","year":"2024","unstructured":"Rajagopal A, Ayanian S, Ryu AJ, et al.. Machine learning operations in health care: a scoping review. Mayo Clin Proc Digit Health. 2024, 2:421-37. 10.1016\/j.mcpdig.2024.06.009","journal-title":"Mayo Clin Proc Digit Health"},{"key":"ref80","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.100950","article-title":"Artificial intelligence in hematologic malignancies: opportunities, challenges, and clinical integration","volume":"18","author":"Salem A","year":"2026","unstructured":"Salem A, Teama M, Kassem HA, Vakilzadehian N, Mahmoud Abdelaziz Ali A, Venugopal D, M Khalifa A. Artificial intelligence in hematologic malignancies: opportunities, challenges, and clinical integration. Cureus. 2026, 18:e100950. 10.7759\/cureus.100950","journal-title":"Cureus"},{"key":"ref81","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(19)30052-6","article-title":"Treatment-free remission in chronic myeloid leukaemia and patient-reported outcomes","volume":"6","author":"Breccia M","year":"2019","unstructured":"Breccia M, Efficace F, Sica S, et al.. Treatment-free remission in chronic myeloid leukaemia and patient-reported outcomes. Lancet Haematol. 2019, 6:225-226. 10.1016\/S2352-3026(19)30052-6","journal-title":"Lancet Haematol"},{"key":"ref82","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13092567","article-title":"Treatment-Free Remission in Chronic Myeloid Leukemia","volume":"13","author":"Bourne G","year":"2024","unstructured":"Bourne G, Bhatia R, Jamy O. Treatment-Free Remission in Chronic Myeloid Leukemia. J Clin Med. 2024, 13:10.3390\/jcm13092567","journal-title":"J Clin Med"},{"key":"ref83","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020009050","article-title":"A phase 3 double-blind study of the addition of tocilizumab vs placebo to cyclosporin\/methotrexate GVHD prophylaxis","volume":"137","author":"Kennedy GA","year":"2021","unstructured":"Kennedy GA, Tey SK, Buizen L, et al.. A phase 3 double-blind study of the addition of tocilizumab vs placebo to cyclosporin\/methotrexate GVHD prophylaxis. Blood. 2021, 137:1970-9. 10.1182\/blood.2020009050","journal-title":"Blood"},{"key":"ref84","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-025-02664-w","article-title":"2025 European LeukemiaNet recommendations for the management of chronic myeloid leukemia","volume":"39","author":"Apperley JF","year":"2025","unstructured":"Apperley JF, Milojkovic D, Cross NC, et al.. 2025 European LeukemiaNet recommendations for the management of chronic myeloid leukemia. Leukemia. 2025, 39:1797-813. 10.1038\/s41375-025-02664-w","journal-title":"Leukemia"},{"key":"ref85","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2024.12.005","article-title":"The cost-effectiveness of frontline tyrosine kinase inhibitors for patients with chronic myeloid leukemia: in pursuit of treatment-free remission and dose reduction","volume":"28","author":"Metsemakers SJ","year":"2025","unstructured":"Metsemakers SJ, Hermens RP, Ector GI, Blijlevens NM, Govers TM. The cost-effectiveness of frontline tyrosine kinase inhibitors for patients with chronic myeloid leukemia: in pursuit of treatment-free remission and dose reduction. Value Health. 2025, 28:224-32. 10.1016\/j.jval.2024.12.005","journal-title":"Value Health"},{"key":"ref86","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1511603","article-title":"Cost-effectiveness of tyrosine kinase inhibitor treatment strategies for chronic myeloid leukemia in South Africa","volume":"15","author":"Woudberg R","year":"2024","unstructured":"Woudberg R, Sinanovic E. Cost-effectiveness of tyrosine kinase inhibitor treatment strategies for chronic myeloid leukemia in South Africa. Front Pharmacol. 2024, 15:1511603. 10.3389\/fphar.2024.1511603","journal-title":"Front Pharmacol"},{"key":"ref87","doi-asserted-by":"publisher","DOI":"10.1016\/j.farma.2024.03.008","article-title":"Asciminib for third-line treatment of chronic myeloid leukemia: cost-effectiveness analysis based on treatment-free remission approach","volume":"48","author":"Garcia Molina A","year":"2024","unstructured":"Garcia Molina A. Asciminib for third-line treatment of chronic myeloid leukemia: cost-effectiveness analysis based on treatment-free remission approach. Farm Hosp. 2024, 48:222-9. 10.1016\/j.farma.2024.03.008","journal-title":"Farm Hosp"},{"key":"ref88","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.01647","article-title":"European Stop Tyrosine Kinase Inhibitor Trial (EURO-SKI) in in chronic myeloid leukemia: final analysis and novel prognostic factors for treatment-free remission","volume":"42","author":"Mahon FX","year":"2024","unstructured":"Mahon FX, Pfirrmann M, Dulucq S, et al.. European Stop Tyrosine Kinase Inhibitor Trial (EURO-SKI) in in chronic myeloid leukemia: final analysis and novel prognostic factors for treatment-free remission. J Clin Oncol. 2024, 42:1875-80. 10.1200\/JCO.23.01647","journal-title":"J Clin Oncol"},{"key":"ref89","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcpo.2025.100613","article-title":"Budget impact analysis of treatment-free remission in chronic myeloid leukemia patients treated with nilotinib in Tunisia","volume":"45","author":"Hizem A","year":"2025","unstructured":"Hizem A, Keskes M, Felfel H. Budget impact analysis of treatment-free remission in chronic myeloid leukemia patients treated with nilotinib in Tunisia. J Cancer Policy. 2025, 45:100613. 10.1016\/j.jcpo.2025.100613","journal-title":"J Cancer Policy"},{"key":"ref90","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2025029876","article-title":"Artificial intelligence in hematology","volume":"146","author":"Nazha A","year":"2025","unstructured":"Nazha A, Elemento O, Ahuja S, et al.. Artificial intelligence in hematology. Blood. 2025, 146:2283-92. 10.1182\/blood.2025029876","journal-title":"Blood"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/465253-digital-medicine-and-artificial-intelligence-in-chronic-myeloid-leukemia-current-applications-challenges-and-future-directions","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T10:22:13Z","timestamp":1771582933000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/465253-digital-medicine-and-artificial-intelligence-in-chronic-myeloid-leukemia-current-applications-challenges-and-future-directions"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,20]]},"references-count":90,"URL":"https:\/\/doi.org\/10.7759\/cureus.103951","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2,20]]}}}